Philip Rosen, MD
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,515 of the $3,100 with a category attached, or 81.1%. It is spread thinly across 35 manufacturers, the largest accounting for just 20.0% — the pattern of someone who eats at a lot of different presentations.
Across 122 payments — averaging $25.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$621
- Intuitive Surgical$472
- AbbVie$245
- Sumitomo Pharma America, Inc.$160
- Dendreon Pharmaceuticals LLC$148
- Merck$131
- plus $1K from 29 others
Across 1 payment — averaging $8135.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Spectrum Pharmaceuticals Inc.$8K
What the payments were for
- Travel & lodging$32811%
- Food & beverage$2,51581%
- Education$2578%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 21 | $621 |
| Intuitive Surgical | 3 | $472 |
| AbbVie(2 entities) | 14 | $245 |
| Sumitomo Pharma America, Inc. | 6 | $160 |
| Dendreon Pharmaceuticals LLC | 6 | $148 |
| Merck | 5 | $131 |
| Myriad Genetic Laboratories, Inc. | 7 | $116 |
| Accord Healthcare, Inc. | 5 | $107 |
| Pfizer | 6 | $96 |
| Tolmar, Inc. | 5 | $81 |
| Johnson & Johnson | 3 | $74 |
| Amgen | 3 | $73 |
| Sun Pharmaceutical Industries Inc. | 2 | $69 |
| Ferring Pharmaceuticals Inc. | 3 | $69 |
| Laborie Medical Technologies Corp. | 2 | $65 |
| Verity Pharmaceuticals Inc. | 3 | $60 |
| AstraZeneca | 2 | $59 |
| 180 Medical, Inc. | 2 | $57 |
| Coloplast | 3 | $51 |
| Boston Scientific | 3 | $47 |
| Rochester Medical Corporation | 2 | $38 |
| Cook Medical LLC | 2 | $38 |
| Smith+Nephew | 1 | $32 |
| Agiliti Surgical, Inc. | 1 | $25 |
| Novartis | 1 | $22 |
| Janssen Scientific Affairs, LLC | 1 | $18 |
| Baxter Healthcare | 1 | $18 |
| EDAP Technomed Inc | 1 | $17 |
| Endo Pharmaceuticals Inc. | 1 | $17 |
| Tempus AI, Inc | 1 | $14 |
| Photocure Inc | 1 | $14 |
| Axonics, Inc. | 1 | $13 |
| Urogen Pharma, Inc. | 1 | $13 |
| Tolmar Pharmaceuticals, Inc. | 1 | $13 |
| Travere Therapeutics, Inc. | 2 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,100 in reported general payments places this provider in the 65th percentile of 153 urology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 35 | $490,792 |
| ErleadaApalutamide | 27 | $399,767 |
| MyrbetriqMirabegron | 388 | $355,451 |
| GemtesaVibegron | 144 | $129,342 |
| Tamsulosin Hcl | 1,344 | $22,000 |
| Mirabegron ErMirabegron | 23 | $20,555 |
| Trospium Chloride | 60 | $5,616 |
| Finasteride | 386 | $5,442 |
| Oxybutynin Chloride | 157 | $3,112 |
| Tolterodine Tartrate ErTolterodine Tartrate | 50 | $2,982 |
| Solifenacin Succinate | 69 | $2,947 |
| Estradiol | 43 | $2,573 |
| Cephalexin | 214 | $2,133 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 30 | $1,966 |
| Dutasteride | 66 | $1,675 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $621 | $846,242423 claims |
| Johnson & JohnsonErleada | $74 | $399,76727 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $160 | $129,342144 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 153 urology providers in Oregon.
Other urology in Salem
- Bradley WarnerSalem$8K
- John MhoonSalem$5K
- Bryan MehlhaffSpringfield$1M
- Lance MarrPortland$323K
- Matt AshleyBend$212K
- da David JiangPortland$65K
- Kim ThaiMedford$57K
- Kevin KrughoffSpringfield$54K
- Kyle GillisClackamas$51K
- Amir PatelPortland$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.